Aristeia Capital L.L.C. Makes New $10.89 Million Investment in Drugs Made In America Acquisition II Corp. $DMII

Aristeia Capital L.L.C. bought a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,100,000 shares of the company’s stock, valued at approximately $10,890,000.

Several other institutional investors also recently modified their holdings of the business. AQR Arbitrage LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth approximately $11,399,000. Polar Asset Management Partners Inc. acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $14,850,000. HBK Investments L P bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $4,950,000. Ghisallo Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $7,425,000. Finally, Radcliffe Capital Management L.P. acquired a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $5,699,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

Shares of DMII stock opened at $10.10 on Thursday. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.10. The company has a fifty day moving average price of $10.04.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.